glyburide has been researched along with Stroke in 30 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Blockade of this channel by the small molecule glyburide results in improved survival and neurological outcome in multiple preclinical models of ischemic stroke." | 8.93 | Human Data Supporting Glyburide in Ischemic Stroke. ( Elm, J; Kimberly, WT; Kronenberg, G; Kunte, H; Sheth, KN; Simard, JM, 2016) |
| " In this study, we investigated the possible beneficial effects of lasmiditan and sumatriptan against post-stroke seizures in mice and explored underlying mechanisms in their effects." | 8.12 | Neuroprotective effects of Lasmiditan and Sumatriptan in an experimental model of post-stroke seizure in mice: Higher effects with concurrent opioid receptors or K ( Amanlou, A; Dehpour, AR; Ejtemaei-Mehr, S; Eslami, F; Ghasemi, M; Rahimi, N; Rashidian, A; Shayan, M; Solaimanian, S, 2022) |
| " Glyburide is reported to prevent brain swelling in preclinical rodent models of ischemic stroke through inhibition of a non-selective channel composed of sulfonylurea receptor 1 and transient receptor potential cation channel subfamily M member 4." | 7.80 | Glyburide is associated with attenuated vasogenic edema in stroke patients. ( Battey, TW; Elm, JJ; Furie, KL; Kimberly, WT; Pham, L; Sheth, KN; Singhal, AB; Stern, BJ; Wu, O; Yoo, AJ, 2014) |
| " Here, we seek to identify pharmacodynamic markers of edema that are modified by intravenous (i." | 5.72 | Hypoxanthine is a pharmacodynamic marker of ischemic brain edema modified by glibenclamide. ( Acharjee, A; Ament, Z; Hinson, HE; Irvine, HJ; Kimberly, WT; Molyneaux, BJ; Sheth, KN; Simard, JM; Wolcott, Z, 2022) |
| "In this secondary analysis of the Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial, we report the effect of IV glyburide on adjudicated, edema-related endpoints." | 5.27 | Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial. ( Bevers, MB; Demchuk, AM; Elm, JJ; Hinson, HE; Kimberly, WT; Molyneaux, BJ; Romero, JM; Sheth, KN; Simard, JM; von Kummer, R, 2018) |
| " Blockade of this channel by the small molecule glyburide results in improved survival and neurological outcome in multiple preclinical models of ischemic stroke." | 4.93 | Human Data Supporting Glyburide in Ischemic Stroke. ( Elm, J; Kimberly, WT; Kronenberg, G; Kunte, H; Sheth, KN; Simard, JM, 2016) |
| " In this study, we investigated the possible beneficial effects of lasmiditan and sumatriptan against post-stroke seizures in mice and explored underlying mechanisms in their effects." | 4.12 | Neuroprotective effects of Lasmiditan and Sumatriptan in an experimental model of post-stroke seizure in mice: Higher effects with concurrent opioid receptors or K ( Amanlou, A; Dehpour, AR; Ejtemaei-Mehr, S; Eslami, F; Ghasemi, M; Rahimi, N; Rashidian, A; Shayan, M; Solaimanian, S, 2022) |
| " It is demonstrated that the resulting CXCR4-overexpressing membrane-coated NPs, termed CMNPs, significantly augment the efficacy of glyburide, an anti-edema agent, for stroke treatment." | 3.91 | Targeted Drug Delivery to Stroke via Chemotactic Recruitment of Nanoparticles Coated with Membrane of Engineered Neural Stem Cells. ( Avery, J; Bao, Y; Chen, AT; Deng, G; Du, F; Li, M; Liu, F; Liu, J; Ma, J; Sheth, K; Suh, HW; Wang, H; Wu, P; Zhang, S; Zhou, J; Zhou, Y, 2019) |
| "Using nationwide administrative Danish registries, we followed all individuals without prior stroke or myocardial infarction who initiated metformin and an IS from 1997 through 2009." | 3.81 | Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. ( Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015) |
| " Glyburide is reported to prevent brain swelling in preclinical rodent models of ischemic stroke through inhibition of a non-selective channel composed of sulfonylurea receptor 1 and transient receptor potential cation channel subfamily M member 4." | 3.80 | Glyburide is associated with attenuated vasogenic edema in stroke patients. ( Battey, TW; Elm, JJ; Furie, KL; Kimberly, WT; Pham, L; Sheth, KN; Singhal, AB; Stern, BJ; Wu, O; Yoo, AJ, 2014) |
| " Total bolus osmotherapy dosing was quantified by "osmolar load"." | 2.94 | Osmotherapy for malignant cerebral edema in a phase 2 prospective, double blind, randomized, placebo-controlled study of IV glibenclamide. ( Demchuk, A; Hinson, HE; Molyneaux, BJ; Romero, J; Sheth, KN; Sun, E; Taylor Kimberly, W; von Kummer, R, 2020) |
| " Safety outcomes are all-cause 30-day mortality and early neurological deterioration, with a focus on cardiac- and glucose-related serious adverse events." | 2.94 | Safety and efficacy of glibenclamide combined with rtPA in acute cerebral ischemia with occlusion/stenosis of anterior circulation (SE-GRACE): study protocol for a randomized controlled trial. ( Chen, P; Huang, K; Huang, W; Huang, Y; Ji, Z; Li, G; Pan, S; Weng, G; Wu, Y; Yang, G; Yang, Z; Zhou, S, 2020) |
| " We compared the effects of three SU medications and initial SU doses on adverse glycemic and cardiovascular events among NH residents." | 1.91 | Comparative safety of sulfonylureas among U.S. nursing home residents. ( Berry, SD; Hayes, KN; Munshi, MN; Riester, MR; Zullo, AR, 2023) |
| "Improved treatment of stroke requires efficient delivery of multimodal therapy to ischemic brain tissue with high specificity." | 1.72 | Brain Targeting, Antioxidant Polymeric Nanoparticles for Stroke Drug Delivery and Therapy. ( Gao, X; Jiang, Z; Mohammed, FS; Peng, B; Qin, Z; Sheth, KN; Wu, H; Zhou, J, 2022) |
| " Here, we seek to identify pharmacodynamic markers of edema that are modified by intravenous (i." | 1.72 | Hypoxanthine is a pharmacodynamic marker of ischemic brain edema modified by glibenclamide. ( Acharjee, A; Ament, Z; Hinson, HE; Irvine, HJ; Kimberly, WT; Molyneaux, BJ; Sheth, KN; Simard, JM; Wolcott, Z, 2022) |
| "Treatment with glyburide is associated with increased all-cause and cardiovascular mortality in patients with T2DM." | 1.46 | All-Cause and Cardiovascular Mortality following Treatment with Metformin or Glyburide in Patients with Type 2 Diabetes Mellitus. ( Esteghamati, A; Heidari, B; Larry, M; Mansournia, MA; Nakhjavani, M; Nargesi, AA; Rabizadeh, S; Raee, MR; Zarifkar, M, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (13.33) | 29.6817 |
| 2010's | 19 (63.33) | 24.3611 |
| 2020's | 7 (23.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, H | 1 |
| Peng, B | 1 |
| Mohammed, FS | 1 |
| Gao, X | 1 |
| Qin, Z | 1 |
| Sheth, KN | 11 |
| Zhou, J | 3 |
| Jiang, Z | 1 |
| Irvine, HJ | 1 |
| Acharjee, A | 1 |
| Wolcott, Z | 1 |
| Ament, Z | 1 |
| Hinson, HE | 4 |
| Molyneaux, BJ | 4 |
| Simard, JM | 11 |
| Kimberly, WT | 7 |
| Shayan, M | 1 |
| Eslami, F | 1 |
| Amanlou, A | 1 |
| Solaimanian, S | 1 |
| Rahimi, N | 1 |
| Rashidian, A | 1 |
| Ejtemaei-Mehr, S | 1 |
| Ghasemi, M | 1 |
| Dehpour, AR | 1 |
| Zullo, AR | 2 |
| Riester, MR | 2 |
| Hayes, KN | 2 |
| Munshi, MN | 2 |
| Berry, SD | 2 |
| Vorasayan, P | 1 |
| Bevers, MB | 2 |
| Beslow, LA | 1 |
| Sze, G | 1 |
| von Kummer, R | 3 |
| Sun, E | 1 |
| Demchuk, A | 1 |
| Romero, J | 1 |
| Taylor Kimberly, W | 1 |
| Huang, K | 2 |
| Ji, Z | 2 |
| Wu, Y | 2 |
| Huang, Y | 1 |
| Li, G | 1 |
| Zhou, S | 1 |
| Yang, Z | 1 |
| Huang, W | 2 |
| Yang, G | 1 |
| Weng, G | 1 |
| Chen, P | 1 |
| Pan, S | 2 |
| Wen, L | 1 |
| Huang, B | 1 |
| Tu, R | 1 |
| Wan, K | 1 |
| Zhang, H | 1 |
| Zhang, X | 1 |
| Peng, J | 1 |
| Deng, X | 1 |
| Yu, JH | 1 |
| Wang, JX | 1 |
| Wang, JP | 1 |
| Yang, SB | 1 |
| Liu, X | 1 |
| Wang, L | 1 |
| Zhang, Y | 1 |
| Zhou, XY | 1 |
| Yang, H | 1 |
| He, YZ | 1 |
| Xu, FY | 1 |
| Kaurav, H | 1 |
| Kapoor, DN | 1 |
| Guo, X | 1 |
| Deng, G | 2 |
| Liu, J | 3 |
| Zou, P | 1 |
| Du, F | 2 |
| Liu, F | 2 |
| Chen, AT | 2 |
| Hu, R | 1 |
| Li, M | 2 |
| Zhang, S | 2 |
| Tang, Z | 1 |
| Han, L | 1 |
| Chen, Q | 1 |
| Gou, X | 1 |
| Demchuk, AM | 1 |
| Romero, JM | 1 |
| Elm, JJ | 3 |
| Hu, Y | 1 |
| Wang, S | 1 |
| Lin, Z | 1 |
| Xu, J | 1 |
| Ma, J | 1 |
| Bao, Y | 1 |
| Suh, HW | 1 |
| Avery, J | 1 |
| Zhou, Y | 1 |
| Wu, P | 1 |
| Sheth, K | 1 |
| Wang, H | 1 |
| Battey, TW | 1 |
| Pham, L | 1 |
| Wu, O | 1 |
| Yoo, AJ | 2 |
| Furie, KL | 1 |
| Singhal, AB | 1 |
| Stern, BJ | 3 |
| del Zoppo, GJ | 1 |
| Jacobson, S | 2 |
| Gerzanich, V | 5 |
| Kent, TA | 1 |
| Mandava, P | 1 |
| Thomalla, G | 1 |
| Campbell, B | 1 |
| Donnan, GA | 1 |
| Davis, SM | 1 |
| Albers, GW | 1 |
| Khanna, A | 1 |
| Walcott, BP | 1 |
| Kahle, KT | 1 |
| Mogensen, UM | 1 |
| Andersson, C | 1 |
| Fosbøl, EL | 1 |
| Schramm, TK | 1 |
| Vaag, A | 1 |
| Scheller, NM | 1 |
| Torp-Pedersen, C | 1 |
| Gislason, G | 1 |
| Køber, L | 1 |
| Caffes, N | 1 |
| Kurland, DB | 1 |
| Elm, J | 1 |
| Kronenberg, G | 1 |
| Kunte, H | 1 |
| Nicholson, JD | 1 |
| Guo, Y | 1 |
| Bernstein, SL | 1 |
| Raee, MR | 1 |
| Nargesi, AA | 1 |
| Heidari, B | 1 |
| Mansournia, MA | 1 |
| Larry, M | 1 |
| Rabizadeh, S | 1 |
| Zarifkar, M | 1 |
| Esteghamati, A | 1 |
| Nakhjavani, M | 1 |
| Hallevi, H | 1 |
| Aronowski, J | 1 |
| Yurovsky, V | 2 |
| Tsymbalyuk, N | 3 |
| Melnichenko, L | 1 |
| Ivanova, S | 3 |
| Tsymbalyuk, O | 1 |
| Ben-Ari, S | 1 |
| Ofek, K | 1 |
| Barbash, S | 1 |
| Meiri, H | 1 |
| Kovalev, E | 1 |
| Greenberg, DS | 1 |
| Soreq, H | 1 |
| Shoham, S | 1 |
| Chen, M | 1 |
| Tarasov, KV | 1 |
| Bhatta, S | 1 |
| Melnitchenko, L | 1 |
| West, GA | 1 |
| Ahmad, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Multi-Center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema[NCT01794182] | Phase 2 | 86 participants (Actual) | Interventional | 2013-06-13 | Completed | ||
| Safety and Efficacy of Glibenclamide Combined With Rt-PA in Treating Acute Ischemic Stroke: a Prospective, Randomized, Double-blind, Placebo-control, Multi-center Study[NCT03284463] | Phase 2/Phase 3 | 306 participants (Actual) | Interventional | 2018-01-01 | Completed | ||
| A Multi-Center, Prospective, Open Label, Phase IIa Trial of RP-1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Experience Clinically Significant Brain Swelling.[NCT01268683] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2011-05-26 | Completed | ||
| Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study[NCT03000283] | Phase 1 | 7 participants (Actual) | Interventional | 2017-03-22 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01268683)
Timeframe: Baseline, Day 1, Day 2, and Day 3 (Day 3 reported)
| Intervention | Cm^3 (Mean) |
|---|---|
| RP-1127 (Glyburide for Injection) | 60.30 |
(NCT01268683)
Timeframe: Up to Day 3
| Intervention | Number of MRIs (Mean) |
|---|---|
| RP-1127 (Glyburide for Injection) | 3.9 |
(NCT01268683)
Timeframe: Up to Day 90
| Intervention | Number of Participants (Number) |
|---|---|
| RP-1127 (Glyburide for Injection) | 2 |
(NCT01268683)
Timeframe: Up to Day 3
| Intervention | Percentage of Participants (Number) |
|---|---|
| RP-1127 (Glyburide for Injection) | 0 |
(NCT01268683)
Timeframe: Day 1
| Intervention | Percentage of Participants (Number) |
|---|---|
| RP-1127 (Glyburide for Injection) | 5.7 |
(NCT01268683)
Timeframe: Day 90
| Intervention | Percentage of Participants (Number) |
|---|---|
| RP-1127 (Glyburide for Injection) | 80 |
(NCT01268683)
Timeframe: Up to Day 4
| Intervention | Percentage of Participants (Number) |
|---|---|
| RP-1127 (Glyburide for Injection) | 0 |
(NCT01268683)
Timeframe: Up to Day 3
| Intervention | Percentage of Participants (Number) |
|---|---|
| RP-1127 (Glyburide for Injection) | 90 |
(NCT01268683)
Timeframe: Up to Day 4
| Intervention | Percentage of Participants (Number) |
|---|---|
| RP-1127 (Glyburide for Injection) | 0 |
The number of months to enroll 10 participants. (NCT01268683)
Timeframe: Day 1
| Intervention | Months (Number) |
|---|---|
| RP-1127 (Glyburide for Injection) | 9.6 |
(NCT01268683)
Timeframe: Baseline, Day 1, Day 2, and Day 3
| Intervention | Cm^3 (Mean) | |||
|---|---|---|---|---|
| Baseline | Day 1 | Day 2 | Day 3 | |
| RP-1127 (Glyburide for Injection) | 101.76 | 141.62 | 152.31 | 169.73 |
(NCT01268683)
Timeframe: Day 1, Day 2, and Day 3
| Intervention | Number of Events (Number) | |||
|---|---|---|---|---|
| Hemorrhagic Infarction Type 1 | Hemorrhagic Infarction Type 2 | Parenchymal Hematoma Type 1 | Parenchymal Hematoma Type 2 | |
| RP-1127 (Glyburide for Injection) | 3 | 8 | 0 | 0 |
The FOUR Score is a 17-point scale (with potential scores ranging from 0 - 16). Decreasing FOUR Score is associated with worsening level of consciousness. The FOUR Score assesses four domains of neurological function: eye responses, motor responses, brainstem reflexes, and breathing pattern. (NCT01268683)
Timeframe: Baseline, Day 1, Day 2, Day 3, and Day 7
| Intervention | Score on a Scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 1 | Day 2 | Day 3 | Day 7 | |
| RP-1127 (Glyburide for Injection) | 15.1 | 14.5 | 14.6 | 14.6 | 14.8 |
The GCS is scored on a scale between 3 and 15 (3 = the worst, and 15 = best). It is composed of three parameters : Best Eye Response (scored on a scale of 1-4), Best Verbal Response (scored on a scale of 1-5), Best Motor Response (scored on a scale of 1-6) (NCT01268683)
Timeframe: Baseline, Day 1, Day 2, Day 3, and Day 7
| Intervention | Score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 1 | Day 2 | Day 3 | Day 7 | |
| RP-1127 (Glyburide for Injection) | 12.5 | 11.9 | 12.5 | 12.8 | 13.5 |
(NCT01268683)
Timeframe: Baseline, Day 1, Day 2, and Day 3
| Intervention | Centimeters cubed (cm^3) (Mean) | |||
|---|---|---|---|---|
| Baseline | Day 1 | Day 2 | Day 3 | |
| RP-1127 (Glyburide for Injection) | 135.20 | 156.78 | 165.38 | 181.71 |
(NCT01268683)
Timeframe: Baseline, Day 1, Day 2, and Day 3
| Intervention | Cm^3 (Mean) | |||
|---|---|---|---|---|
| Baseline | Day 1 | Day 2 | Day 3 | |
| RP-1127 (Glyburide for Injection) | 11.78 | 9.25 | 8.92 | 10.07 |
(NCT01268683)
Timeframe: Baseline, Day 1, Day 2, and Day 3
| Intervention | Millimeters (mm) (Mean) | |||
|---|---|---|---|---|
| Baseline | Day 1 | Day 2 | Day 3 | |
| RP-1127 (Glyburide for Injection) | 0.56 | 2.00 | 2.63 | 2.50 |
The NIHSS is composed of 11 categories, each of which is scored between 0 and 4. A score of 0 indicates normal function, a higher score indicates more impairment. Category scores are summed to generate the total NIHSS score (possibles scores range from 0-42). (NCT01268683)
Timeframe: Baseline, Day 1, Day 2, Day 3, and Day 7
| Intervention | Score on a Scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 1 | Day 2 | Day 3 | Day 7 | |
| RP-1127 (Glyburide for Injection) | 17.8 | 18.4 | 15.6 | 16.2 | 13.9 |
The mRS scale runs from 0-6, the scoring is as follows: 0 - No symptoms, 1 - No significant disability, 2 - Slight disability, 3 - Moderate disability, 4 - Moderately severe disability, 5 - Severe disability, 6 - Dead (NCT01268683)
Timeframe: Day 30, Day 90
| Intervention | Number of Participants (Number) | |
|---|---|---|
| Day 30 | Day 90 | |
| RP-1127 (Glyburide for Injection) | 9 | 8 |
Adverse Events (AE's) of special interest (cardiac events, difficulty controlling blood sugar, liver problems, and blood disorders, including anemia) will be followed for 30 days and all Severe Adverse Events (SAE's) will be followed for 90 days. SAE's and AE's were reviewed, and the number of participants with unanticipated adverse events, or drug-related SAE's were assessed. (NCT01268683)
Timeframe: Up to Day 90
| Intervention | Number of Participants (Number) | |
|---|---|---|
| Adverse Events | Serious Adverse Events | |
| RP-1127 (Glyburide for Injection) | 10 | 3 |
Changes in cerebral edema (CE) as measured on CT. Goal is a -5 to -10% change in CE over time. Change will be measured both as absolute change in volume, calculated as the final volume minus the baseline volume measure and converted to a percentage of the baseline volume measure. (NCT03000283)
Timeframe: Baseline to 168 hours post-enrollment
| Intervention | percentage of change from baseline (Mean) |
|---|---|
| Conivaptan Treatment Group | -37.1 |
Cost as measured by length of stay in the neuro ICU. (NCT03000283)
Timeframe: Enrollment through hospital discharge, up to 3 weeks
| Intervention | days (Mean) |
|---|---|
| Conivaptan Treatment Group | 14.4 |
All-cause deaths during hospitalization (NCT03000283)
Timeframe: Enrollment through hospital discharge, up to 3 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Conivaptan Treatment Group | 0 |
Modified Rankin Scale (0 to 6) at discharge from the hospital. A score of 0 indicates no disability and a score of 6 indicates the patient died. Functional independence is defined as a score of 2 or less. (NCT03000283)
Timeframe: At discharge from ICU and from hospital, up to 3 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Conivaptan Treatment Group | 5 |
"Cost as measured by:~Need for external ventricular drain (EVD)/bolt or surgical procedures (craniectomy, clot evacuation,VPS) for reduction/management of CE.~Need for central venous lines, arterial lines, peripherally inserted central venous catheter (PICC) lines, tracheostomy/percutaneous endoscopic gastrostomies (PEGs).~Number of patients requiring a ventilator." (NCT03000283)
Timeframe: Baseline to 168 hours post-enrollment
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| EVD/bolt or surgical procedures | Lines or tracheostomy/PEG | Ventilator | |
| Conivaptan Treatment Group | 0 | 7 | 1 |
The number of participants with abnormal seizure activity and/or abnormal lab values and/or increase in infection rate and/or any drug-related adverse events. (NCT03000283)
Timeframe: Baseline to 168 hours post-enrollment
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Abnormal Seizure Activity | Abnormal Lab Values | Infections | Drug-related Adverse Events | |
| Conivaptan Treatment Group | 0 | 0 | 1 | 0 |
5 reviews available for glyburide and Stroke
| Article | Year |
|---|---|
Implantable systems for drug delivery to the brain.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Drug Carriers; Drug Implants; Glyburide; Humans; Ne | 2017 |
Glibenclamide in cerebral ischemia and stroke.
Topics: Animals; Brain Edema; Brain Ischemia; Glyburide; Humans; Hypoglycemic Agents; Stroke | 2014 |
Effect of glibenclamide on the prevention of secondary brain injury following ischemic stroke in humans.
Topics: Brain Diseases; Brain Edema; Brain Ischemia; Clinical Trials, Phase II as Topic; Glyburide; Humans; | 2014 |
Glibenclamide for the treatment of ischemic and hemorrhagic stroke.
Topics: Animals; Blood-Brain Barrier; Glyburide; Humans; Hypoglycemic Agents; KATP Channels; Stroke; Sulfony | 2015 |
Human Data Supporting Glyburide in Ischemic Stroke.
Topics: Brain Edema; Fibrinolytic Agents; Glyburide; Humans; Hypoglycemic Agents; Intracranial Hemorrhages; | 2016 |
5 trials available for glyburide and Stroke
| Article | Year |
|---|---|
Intravenous Glibenclamide Reduces Lesional Water Uptake in Large Hemispheric Infarction.
Topics: Administration, Intravenous; Aged; Cerebral Infarction; Female; Glyburide; Humans; Male; Middle Aged | 2019 |
Osmotherapy for malignant cerebral edema in a phase 2 prospective, double blind, randomized, placebo-controlled study of IV glibenclamide.
Topics: Administration, Intravenous; Aged; Brain Edema; Decompressive Craniectomy; Double-Blind Method; Fema | 2020 |
Safety and efficacy of glibenclamide combined with rtPA in acute cerebral ischemia with occlusion/stenosis of anterior circulation (SE-GRACE): study protocol for a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Brain Ischemia; Constriction, Pathologic; Double-Blind Method; Female; Fibr | 2020 |
Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial.
Topics: Adult; Aged; Brain Edema; Endpoint Determination; Female; Glyburide; Humans; Male; Middle Aged; Neur | 2018 |
Pilot study of intravenous glyburide in patients with a large ischemic stroke.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Brain Edema; Brain Ischemia; Comorbidity; | 2014 |
Pilot study of intravenous glyburide in patients with a large ischemic stroke.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Brain Edema; Brain Ischemia; Comorbidity; | 2014 |
Pilot study of intravenous glyburide in patients with a large ischemic stroke.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Brain Edema; Brain Ischemia; Comorbidity; | 2014 |
Pilot study of intravenous glyburide in patients with a large ischemic stroke.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Brain Edema; Brain Ischemia; Comorbidity; | 2014 |
20 other studies available for glyburide and Stroke
| Article | Year |
|---|---|
Brain Targeting, Antioxidant Polymeric Nanoparticles for Stroke Drug Delivery and Therapy.
Topics: Antioxidants; Brain; Drug Delivery Systems; Glyburide; Humans; Nanoparticles; Polymers; Stroke | 2022 |
Hypoxanthine is a pharmacodynamic marker of ischemic brain edema modified by glibenclamide.
Topics: Administration, Intravenous; Biomarkers; Brain Edema; Glyburide; Humans; Hypoxanthine; Matrix Metall | 2022 |
Neuroprotective effects of Lasmiditan and Sumatriptan in an experimental model of post-stroke seizure in mice: Higher effects with concurrent opioid receptors or K
Topics: Adenosine Triphosphate; Animals; Anticonvulsants; bcl-2-Associated X Protein; Benzamides; Disease Mo | 2022 |
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Effectiveness and safety of glibenclamide for stroke: protocol for a systematic review and meta-analysis.
Topics: China; Glyburide; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Randomized Controlled Trials | 2021 |
Irisin protects against neuronal injury induced by oxygen-glucose deprivation in part depends on the inhibition of ROS-NLRP3 inflammatory signaling pathway.
Topics: Animals; Brain Ischemia; Fibronectins; Glucose; Glyburide; HeLa Cells; Humans; Inflammation; Neurons | 2017 |
Thrombin-Responsive, Brain-Targeting Nanoparticles for Improved Stroke Therapy.
Topics: Animals; Brain Ischemia; Drug Delivery Systems; Glyburide; Hypoglycemic Agents; Male; Mice; Mice, In | 2018 |
Exploratory analysis of oral glibenclamide in acute ischemic stroke.
Topics: Administration, Oral; Adult; Aged; Brain Ischemia; Case-Control Studies; Female; Glyburide; Humans; | 2019 |
Targeted Drug Delivery to Stroke via Chemotactic Recruitment of Nanoparticles Coated with Membrane of Engineered Neural Stem Cells.
Topics: Animals; Cell Membrane; Chemokine CXCL12; Chemotaxis; Drug Delivery Systems; Glyburide; Humans; Mice | 2019 |
Novel approaches to the primary prevention of edema after ischemia.
Topics: ATP-Binding Cassette Transporters; Brain Edema; Brain Ischemia; Clinical Trials, Phase II as Topic; | 2013 |
Glyburide is associated with attenuated vasogenic edema in stroke patients.
Topics: Adult; Aged; Biomarkers; Brain Edema; Brain Ischemia; Case-Control Studies; Clinical Trials as Topic | 2014 |
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combina | 2015 |
SUR1-Associated Mechanisms Are Not Involved in Ischemic Optic Neuropathy 1 Day Post-Injury.
Topics: Animals; Central Nervous System; Glyburide; Hypoglycemic Agents; Immunohistochemistry; Mice, Inbred | 2016 |
All-Cause and Cardiovascular Mortality following Treatment with Metformin or Glyburide in Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Cohort Studies; Coronary Angiography; Coronary Artery | 2017 |
Life after SAINT.
Topics: Albumins; Antioxidants; Benzenesulfonates; Caffeine; Cerebral Hemorrhage; Clinical Trials, Phase II | 2007 |
Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke.
Topics: Animals; ATP-Binding Cassette Transporters; Brain; Brain Ischemia; Cerebral Infarction; Data Interpr | 2009 |
Glibenclamide is superior to decompressive craniectomy in a rat model of malignant stroke.
Topics: Animals; Decompressive Craniectomy; Disease Models, Animal; Glyburide; Male; Rats; Rats, Wistar; Str | 2010 |
Similar cation channels mediate protection from cerebellar exitotoxicity by exercise and inheritance.
Topics: Animals; Cerebellum; Cyclic Nucleotide-Gated Cation Channels; Excitatory Amino Acid Agonists; Gene E | 2012 |
Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke.
Topics: Adenosine Triphosphate; Animals; Astrocytes; ATP-Binding Cassette Transporters; Brain Edema; Brain I | 2006 |
Acetazolamide and enalapril combination offers complete protection from nitric oxide-deficient stroke in stroke-prone spontaneously hypertensive rats.
Topics: Acetazolamide; Angiotensin-Converting Enzyme Inhibitors; Animals; Barium Compounds; Blood Pressure; | 2000 |